InterMune Inc (NASDAQ:ITMN), EVP Sean P. Nolan sold 20,000 shares of the stock on the open market in a transaction dated Friday, June 13th. The stock was sold at an average price of $42.80, for a total transaction of $856,000.00. Following the completion of the transaction, the executive vice president now directly owns 65,671 shares in the company, valued at approximately $2,810,719. InterMune Inc (NASDAQ:ITMN), weekly performance is 12.32%. On last trading day company shares ended up $47.22. Analysts mean target price for the company is $42.08. InterMune Inc (NASDAQ:ITMN), distance from 50-day simple moving average (SMA50) is 32.30%.
BioDelivery Sciences International, Inc. (NASDAQ:BDSI), Director Samuel P. Sears, Jr. unloaded 5,000 shares of the stock on the open market in a transaction dated Thursday, June 12th. The shares were sold at an average price of $12.33, for a total transaction of $61,650.00. Following the completion of the transaction, the director now directly owns 14,853 shares in the company, valued at approximately $183,137. BioDelivery Sciences International, Inc. (NASDAQ:BDSI), advanced 0.20% in last trading session and ended the day on $12.51. BDSI, Gross Margin is 92.10% and its return on assets is -81.90%. BioDelivery Sciences International, Inc. (NASDAQ:BDSI), quarterly performance is 38.48%.
Enanta Pharmaceuticals Inc (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced that AbbVie has reported that the Marketing Authorization Applications (MAAs) for AbbVie’s investigational, all-oral, interferon-free regimen primarily for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection have been fully validated and are now under accelerated assessment by the European Medicines Agency (EMA). Enanta Pharmaceuticals Inc (NASDAQ:ENTA), shares moved up 6.04% in last trading session and was closed at $44.24, while trading in range of $40.75 – 44.48. Enanta Pharmaceuticals Inc (NASDAQ:ENTA), year to date (YTD) performance is 62.17%.
Applied Genetic Technologies Corp (NASDAQ:AGTC), has not announced any significant development of any of its clinical studies in the current month. Its loss in the third quarter was also wider than the Street expectations, though revenue more than doubled to $232K from $116K. Applied Genetic Technologies Corp (NASDAQ:AGTC), ended the last trading day at $31.69. Company weekly volatility is calculated as 12.95% and price to cash ratio as 18.21. Applied Genetic Technologies Corp (NASDAQ:AGTC), showed a positive weekly performance of 31.77%.